Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 363 shares of common stock to cover tax withholding on restricted stock units.

Summary

• On February 11, 2025, Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 363 shares of the company's common stock.
• The sale was executed at a price of $28.5388 per share.
• This transaction was conducted to cover tax withholding obligations related to the release of restricted stock units on January 10, 2025.
• Following the transaction, DeLong directly owns 83,945 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Apellis Pharmaceuticals, Mark Jeffrey DeLong, insider trading, Form 4, stock sale, tax withholding, APLS, restricted stock units